Holen Sie sich die Stockscreener-App
0.34
2.13%
-0.0049
Schlusskurs vom Vortag:
$0.3449
Offen:
$0.3452
24-Stunden-Volumen:
52,546
Relative Volume:
0.21
Marktkapitalisierung:
$1.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.91M
KGV:
-0.0036
EPS:
-94.5617
Netto-Cashflow:
$-12.02M
1W Leistung:
-3.89%
1M Leistung:
-81.95%
6M Leistung:
-98.28%
1J Leistung:
-99.33%
1-Tages-Spanne:
$0.335
$0.3557
1-Wochen-Bereich:
$0.335
$0.38
52-Wochen-Spanne:
$0.335
$77.70
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Firmenname
Silexion Therapeutics Corp
Sektor
Branche
Telefon
972-8-6286005
Adresse
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.337 | 1.92M | 0 | -12.91M | -12.02M | -94.56 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN) - TipRanks
Silexion (SLXNW) Range: Finishes Nearly Flat at $0.01 in Latest Trading; Next Test - vinanet.vn
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal - TipRanks
Silexion Therapeutics Received Notice of Delisting - TradingView
Top Silexion Therapeutics CorpWarrant (SLXNW) Competitors 2026 - MarketBeat
Silexion Therapeutics Executes Reverse Share Split Amid Strain - The Globe and Mail
Silexion Therapeutics Closes Public Offering and Strengthens Equity - The Globe and Mail
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Moomoo
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com India
Silexion prices $2.5M offering to fund KRAS cancer trial - Dealroom
Silexion Therapeutics prices $2.5M public offering at $0.65 - Investing.com
Silexion Intends to Use Offering Proceeds for Pancreatic Trial - Stock Titan
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants - Quiver Quantitative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls 31%Balance Sheet Strength - vinanet.vn
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - TipRanks
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - Benzinga
Immunotherapy's Biggest Blind Spot Is A $7 Billion Market. Silexion May Have A Way In (NASDAQ: SLXN) - Menafn
Form 8K Silexion Therapeutics Corp For: 10 August By Investing.com - Investing.com South Africa
Silexion Updates SIL204 Clinical and Regulatory Roadmap - tipranks.com
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - Smartkarma
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Hold Rating - 富途牛牛
IPO Databook: Silexion Therapeutics (SLXN US)Aug 2026 - Smartkarma
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Cancer treatment makes tumor vulnerable to immune system attack, research finds - jpost.com
Silexion unveils key SIL204 KRAS preclinical findings - TipRanks
Silexion to present preclinical data on SIL-204 at GI cancer event - Investing.com
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - The Manila Times
Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells - Quiver Quantitative
Silexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock Titan
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance - TipRanks
Silexion Therapeutics restores Nasdaq audit committee compliance with new appointment - TradingView
SLXN Q1 2026 Earnings: Narrower Loss of -8.5 Per Share Beats Consensus by 35.4% as Clinical-Stage Spending Stays in CheckAnalyst Drop Coverage - vinanet.vn
Silexion Therapeutics Announces Board Member Resignation - TipRanks
Silexion Therapeutics Warrant (SLXNW) Holds at $0.02 as Range-Bound Trading PersistsVolatility Stop - dars.gov.et
Finanzdaten der Silexion Therapeutics Corp-Aktie (SLXN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):